Albany Molecular Research Inc. has secured a potential 10-year, $39.5 million contract renewal to support a National Institutes of Health program that aims to develop medicines for nervous system disorders.
AMRI said Tuesday it will continue to provide medicinal chemistry, absorption, distribution, metabolism and excretion services to the Blueprint Neurotherapeutics Network managed by NIH’s National Institute of Neurological Disorders and Stroke.
NIH initially awarded the company a contract for BPN support services in 2011.
The program helps eligible participants receive drug discovery services from multiple NIH-funded contract research organizations.
AMRI’s new contract also includes exploratory chemistry, synthesis, in vitro ADME and toxicity research, computer-aided drug discovery and structure-activity-relationship analysis services.
The company also intends to support NINDS through the Drug Discovery Center of Excellence in New York.
AMRI also supports the National Cancer Institute‘s Chemical Biology Consortium through a subcontract with Leidos‘ biomedical research unit, which operates the NCI-sponsored Frederick National Lab for Cancer Research.